Gigantol inhibits cell proliferation and induces apoptosis by regulating DEK in non‑small cell lung cancer

Cai,Yuxing; Hao,Yi; Xu,Hui; Chen,Kai; Ren,Baozhong

doi:10.3892/etm.2021.10752

Gigantol inhibits cell proliferation and induces apoptosis by regulating DEK in non‑small cell lung cancer

Authors:
- Yuxing Cai
- Yi Hao
- Hui Xu
- Kai Chen
- Baozhong Ren
View Affiliations

Affiliations: Department of Respiratory Medicine, Baoji Center Hospital, Baoji, Shaanxi 721008, P.R. China, Department of Pediatric Surgery, Baoji Maternal and Child Health Care Hospital, Baoji, Shaanxi 721000, P.R. China, Department of Respiratory Medicine, Baoji Traditional Chinese Medicine Hospital, Baoji, Shaanxi 721001, P.R. China
Published online on: September 17, 2021 https://doi.org/10.3892/etm.2021.10752
Article Number: 1317
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is a common type of cancer, with a mortality of >80% worldwide. Gigantol is a bibenzyl compound that displays anticancer activity. The aim of the present study was to determine the biological activity of gigantol in NSCLC and to elucidate the underlying molecular mechanism of its action. The expression of DEK proto‑oncogene (DEK) was measured in NSCLC tissues and cell lines by reverse transcription‑quantitative PCR (RT‑qPCR). The results suggested that DEK levels were significantly increased in NSCLC tissues and cell lines compared with adjacent non‑tumor tissues and BEAS‑2B normal bronchial epithelial cells, respectively. A549 cells were exposed to a series of gigantol concentrations (0, 25, 50 and 100 µM) and transfected with DEK small interfering RNA. The results of cell viability measured by MTT assay indicated that gigantol significantly decreased cell viability. Additionally, cell proliferation was assessed by CCK‑8 and apoptosis was measured by flow cytometry. In comparison with the control group, gigantol treatment inhibited cell proliferation and promoted apoptosis, whereas DEK knockdown increased gigantol‑induced suppression of proliferation and acceleration of apoptosis. Additionally, DEK overexpression reversed gigantol‑induced effects on proliferation and apoptosis. Moreover, compared with the control group, gigantol treatment decreased Ki‑67 and Bcl‑2 expression levels, increased Bax expression levels and inactivated the Wnt/β‑catenin signaling pathway, as assessed by RT‑qPCR and/or western blot. DEK knockdown further increased gigantol‑induced effects, but DEK overexpression reversed gigantol‑induced effects. To conclude, the results of the present study suggested that gigantol inhibited cell proliferation and induced apoptosis by decreasing Ki‑67 and Bcl‑2 expression, increasing Bax expression and activating the Wnt/β‑catenin signaling pathway by regulating DEK. The present study indicated the therapeutic potential of gigantol in patients with NSCLC. In addition, DEK may serve as a novel therapeutic target to enhance the effects of gigantol treatment.

View Figures

View References

1	Carbone DP, Gandara DR, Antonia SJ, Zielinski C and Paz-Ares L: Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy. J Thorac Oncol. 10:974–984. 2015.PubMed/NCBI View Article : Google Scholar
2	Gu H, Chen J, Song Y and Shao H: Gastric adenocarcinoma predictive long intergenic non-coding RNA promotes tumor occurrence and progression in non-small cell lung cancer via regulation of the miR-661/eEF2K signaling pathway. Cell Physiol Biochem. 51:2136–2147. 2018.PubMed/NCBI View Article : Google Scholar
3	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1(15009)2015.PubMed/NCBI View Article : Google Scholar
4	Kumarakulasinghe NB, van Zanwijk N and Soo RA: Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 20:370–378. 2015.PubMed/NCBI View Article : Google Scholar
5	Lam Y, Ng TB, Yao RM, Shi J, Xu K, Sze SC and Zhang KY: Evaluation of chemical constituents and important mechanism of pharmacological biology in Dendrobium plants. Evid Based Compement Alternat Med. 2015(841752)2015.PubMed/NCBI View Article : Google Scholar
6	Chen X, Wang F, Wang Y, Li X, Wang A, Wang C and Guo S: Discrimination of the rare medicinal plant Dendrobium officinale based on naringenin, bibenzyl, and polysaccharides. Sci China Life Sci. 55:1092–1099. 2012.PubMed/NCBI View Article : Google Scholar
7	Zheng S, Zhu Y, Jiao C, Shi M, Wei L, Zhou Y, Jin Q and Cai Y: Extraction and analysis of gigantol from Dendrobium officinale with response surface methodology. Molecules. 23(818)2018.PubMed/NCBI View Article : Google Scholar
8	Ng TB, Liu J, Wong JH, Ye X, Wing Sze SC, Tong Y and Zhang KY: Review of research on Dendrobium, a prized folk medicine. Appl Microbiol Biotechnol. 93:1795–1803. 2012.PubMed/NCBI View Article : Google Scholar
9	Won JH, Kim JY, Yun KJ, Lee JH, Back NI, Chung HG, Chung SA, Jeong TS, Choi MS and Lee KT: Gigantol isolated from the whole plants of Cymbidium goeringii inhibits the LPS-induced iNOS and COX-2 expression via NF-kappaB inactivation in RAW 264.7 macrophages cells. Planta Med. 72:1181–1187. 2006.PubMed/NCBI View Article : Google Scholar
10	Simmler C, Antheaume C and Lobstein A: Antioxidant biomarkers from Vanda coerulea stems reduce irradiated HaCaT PGE-2 production as a result of COX-2 inhibition. PLoS One. 5(e13713)2010.PubMed/NCBI View Article : Google Scholar
11	Fan C, Wang W, Wang Y, Qin G and Zhao W: Chemical constituents from Dendrobium densiflorum. Phytochemistry. 57:1255–1258. 2001.PubMed/NCBI View Article : Google Scholar
12	Wu J, Li X, Wan W, Yang Q, Ma W, Chen D, Hu J, Chen CO and Wei X: Gigantol from Dendrobium chrysotoxum Lindl. binds and inhibits aldose reductase gene to exert its anti-cataract activity: An in vitro mechanistic study. J Ethnopharmacol. 198:255–261. 2017.PubMed/NCBI View Article : Google Scholar
13	Wu J, Li X, Fang H, Yi Y, Chen D, Long Y, Gao X, Wei X and Chen CY: Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract. BMC Complement Altern Med. 16(286)2016.PubMed/NCBI View Article : Google Scholar
14	Yu S, Wang Z, Su Z, Song J, Zhou L, Sun Q, Liu S, Li S, Li Y, Wang M, et al: Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells. BMC Complement Altern Med. 18(59)2018.PubMed/NCBI View Article : Google Scholar
15	Chen H, Huang Y, Huang J, Lin L and Wei G: Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-κB signaling pathway. Oncol Rep. 37:865–870. 2017.PubMed/NCBI View Article : Google Scholar
16	Unahabhokha T, Chanvorachote P and Pongrakhananon V: The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells. Tumour Biol. 37:8633–8641. 2016.PubMed/NCBI View Article : Google Scholar
17	Charoenrungruang S, Chanvorachote P, Sritularak B and Pongrakhananon V: Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells. J Nat Prod. 77:1359–1366. 2014.PubMed/NCBI View Article : Google Scholar
18	von Lindern M, Breems D, van Baal S, Adriaansen H and Grosveld G: Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer. 5:227–234. 1992.PubMed/NCBI View Article : Google Scholar
19	Waldmann T, Scholten I, Kappes F, Hu HG and Knippers R: The DEK protein-an abundant and ubiquitous constituent of mammalian chromatin. Gene. 343:1–9. 2004.PubMed/NCBI View Article : Google Scholar
20	Hu HG, Scholten I, Gruss C and Knippers R: The distribution of the DEK protein in mammalian chromatin. Biochem Biophys Res Commun. 358:1008–1014. 2007.PubMed/NCBI View Article : Google Scholar
21	Riveiro-Falkenbach E and Soengas MS: Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res. 16:2932–2938. 2010.PubMed/NCBI View Article : Google Scholar
22	Liu X, Qi D, Qi J, Mao Z, Li X, Zhang J, Li J and Gao W: Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma. Oncol Rep. 35:155–162. 2016.PubMed/NCBI View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
24	Feng T, Liu Y, Li C, Li Z and Cai H: DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis. Tumour Biol. 39(1010428317716248)2017.PubMed/NCBI View Article : Google Scholar
25	Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC and Wells SI: Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res. 69:1792–1799. 2009.PubMed/NCBI View Article : Google Scholar
26	Hui W, Ma X, Zan Y, Song L, Zhang S and Dong L: MicroRNA-1292-5p inhibits cell growth, migration and invasion of gastric carcinoma by targeting DEK. Am J Cancer Res. 8:1228–1238. 2018.PubMed/NCBI
27	Piao J, Shang Y, Liu S, Piao Y, Cui X, Li Y and Lin Z: High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagn Pathol. 9(67)2014.PubMed/NCBI View Article : Google Scholar
28	Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J and Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13(366)2013.PubMed/NCBI View Article : Google Scholar
29	Zhou QC, Deng XF, Yang J, Jiang H, Qiao MX, Liu HH, Qian Z, Hou LL and Hu HG: Oncogene DEK is highly expressed in lung cancerous tissues and positively regulates cell proliferation as well as invasion. Oncol Lett. 15:8573–8581. 2018.PubMed/NCBI View Article : Google Scholar
30	Bhummaphan N and Chanvorachote P: Gigantol suppresses cancer stem cell-like phenotypes in lung cancer cells. Evid Based Complement Alternat Med. 2015(836564)2015.PubMed/NCBI View Article : Google Scholar
31	Unahabhokha T, Chanvorachote P, Sritularak B, Kitsongsermthon J and Pongrakhananon V: Gigantol inhibits epithelial to mesenchymal process in human lung cancer cells. Evid Based Complement Alternat Med. 2016(4561674)2016.PubMed/NCBI View Article : Google Scholar
32	Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31:13–20. 1983.PubMed/NCBI View Article : Google Scholar
33	Harris MH and Thompson CB: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7:1182–1191. 2000.PubMed/NCBI View Article : Google Scholar
34	Lin L, Piao J, Ma Y, Jin T, Quan C, Kong J, Li Y and Lin Z: Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. PLoS One. 9(e111260)2014.PubMed/NCBI View Article : Google Scholar
35	Stewart DJ: Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 106(djt356)2014.PubMed/NCBI View Article : Google Scholar
36	Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE and Wells SI: The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene. 34:2325–2336. 2015.PubMed/NCBI View Article : Google Scholar